Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
13d
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...
Wegovy is a GLP-1 agonist containing semaglutide ... though it’s not a weight loss medication. Starting dose: 0.25 mg weekly for 4 weeks. Gradually increased to a maximum dose of 2.0 mg weekly.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback